Pelargonium (Umckaloabo) for Cold And Flu Support

Research suggests that Pelargonium sidoides extract (commonly marketed as Umckaloabo, standardized as EPs 7630) may help reduce the severity and duration of symptoms associated with the common cold, acute bronchitis, and other upper respiratory tract infections, with the body of evidence drawing from multiple randomized controlled trials, several Cochrane systematic reviews, and more recent network meta-analyses — nearly all pointing in a supportive direction. Studies indicate that the liquid form of the extract appears more consistently effective than tablet formulations, and a 2023 network meta-analysis rated Pelargonium sidoides as offering the most beneficial effect on common cold symptom improvement among the herbal options studied, with moderate certainty of evidence. However, reviewers across multiple Cochrane analyses have cautioned that overall evidence quality ranges from low to very low due to concerns about study methodology, publication bias, and variability in how outcomes were measured, meaning the positive findings should be interpreted with appropriate caution. Side effects were reported more frequently with Pelargonium sidoides than with placebo in some trials, though none were characterized as serious, and no studies reviewed here were evaluating it as a cure or replacement for conventional medical care.